The Effect of Individualized Precision Therapy Programs in Patients With BTC
The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer
研究概览
详细说明
In this prospective cohort study, patients who are eligible for inclusion criteria will enroll in the study. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification, and then to develop individualized precise treatment programs.
The investigators hope to achieve the following objectives:
① Through the establishment of Individualized Precision Therapy Programs to improve the overall survival of bile duct malignancy (BTC);
② To study the molecular typing of the prognosis of biliary malignancy;
③ To construct a database of BTC gene bank, as well as for drug screening information.
研究类型
注册 (预期的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Shanghai、中国
- 招聘中
- Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Pathological diagnosis of biliary malignancies
- The expected survival time is longer than 3 months
- PKS score> 60 points
- Willing to take part in the study
Exclusion Criteria:
- Can not or refuse to collect tumor samples
- Refused to accept the relevant treatment method
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:IPTP Group
The IPTP Group will receive the Individualized Precision Therapy Programs.
After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct.
Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
|
After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct.
Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall Survival (OS)
大体时间:through study completion, an average of 2 year
|
The time from surgery to all-cause death
|
through study completion, an average of 2 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression-Free Survival (PFS)
大体时间:through study completion, an average of 2 year
|
The time from surgery to recurrence.
|
through study completion, an average of 2 year
|
合作者和调查者
调查人员
- 首席研究员:JIAN WANG, M.D.、Department of Biliary-pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- IPTP-BTC
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.